Literature DB >> 21504505

A novel mutation in the nerve-specific 5'UTR of the GJB1 gene causes X-linked Charcot-Marie-Tooth disease.

Sinéad M Murphy1, James Polke, Hadi Manji, Julian Blake, Lilla Reiniger, Mary Sweeney, Henry Houlden, Sebastian Brandner, Mary M Reilly.   

Abstract

X-linked Charcot-Marie-Tooth disease (CMT1X) is the second most common cause of CMT, and is usually caused by mutations in the gap junction protein beta 1 (GJB1) gene which codes for connexin 32 (CX32). CX32 has three tissue-specific promoters, P1 which is specific for liver and pancreas, P1a specific for liver, oocytes and embryonic stem cells, and P2 which is nerve-specific. Over 300 mutations have been described in GJB1, spread throughout the coding region. We describe two families with X-linked inheritance and a phenotype consistent with CMT1X who did not have mutations in the GJB1 coding region. The non-coding region of GJB1 was sequenced and an upstream exon-splicing variant found at approximately - 373G>A which segregated with the disease in both families and was not present in controls. This substitution is located at the last base of the nerve-specific 5'UTR and thus may disrupt splicing of the nerve-specific transcript. Online consensus splice-site programs predict a reduced score for the mutant sequence vs. the normal sequence. It is likely that other mutations within the GJB1 non-coding regions account for the CMT1X families who do not have coding region mutations.
© 2011 Peripheral Nerve Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21504505     DOI: 10.1111/j.1529-8027.2011.00321.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  10 in total

1.  The role of gap junctions in Charcot-Marie-Tooth disease.

Authors:  Kleopas A Kleopa
Journal:  J Neurosci       Date:  2011-12-07       Impact factor: 6.167

Review 2.  Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review.

Authors:  José Berciano; Antonio García; Elena Gallardo; Kristien Peeters; Ana L Pelayo-Negro; Silvia Álvarez-Paradelo; José Gazulla; Miriam Martínez-Tames; Jon Infante; Albena Jordanova
Journal:  J Neurol       Date:  2017-03-31       Impact factor: 4.849

Review 3.  Dysregulation of ErbB Receptor Trafficking and Signaling in Demyelinating Charcot-Marie-Tooth Disease.

Authors:  Samuel M Lee; Lih-Shen Chin; Lian Li
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

Review 4.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

5.  X inactivation in females with X-linked Charcot-Marie-Tooth disease.

Authors:  Sinéad M Murphy; Richard Ovens; James Polke; Carly E Siskind; Matilde Laurà; Karen Bull; Gita Ramdharry; Henry Houlden; Raymond P J Murphy; Michael E Shy; Mary M Reilly
Journal:  Neuromuscul Disord       Date:  2012-04-06       Impact factor: 4.296

6.  Identification of cis-regulatory sequence variations in individual genome sequences.

Authors:  Rebecca Worsley-Hunt; Virginie Bernard; Wyeth W Wasserman
Journal:  Genome Med       Date:  2011-10-10       Impact factor: 11.117

7.  Application of targeted multi-gene panel testing for the diagnosis of inherited peripheral neuropathy provides a high diagnostic yield with unexpected phenotype-genotype variability.

Authors:  Thalia Antoniadi; Chris Buxton; Gemma Dennis; Natalie Forrester; Debbie Smith; Peter Lunt; Sarah Burton-Jones
Journal:  BMC Med Genet       Date:  2015-09-21       Impact factor: 2.103

8.  Mutations in noncoding regions of GJB1 are a major cause of X-linked CMT.

Authors:  Pedro J Tomaselli; Alexander M Rossor; Alejandro Horga; Zane Jaunmuktane; Aisling Carr; Paola Saveri; Giuseppe Piscosquito; Davide Pareyson; Matilde Laura; Julian C Blake; Roy Poh; James Polke; Henry Houlden; Mary M Reilly
Journal:  Neurology       Date:  2017-03-10       Impact factor: 9.910

Review 9.  Connexins: Synthesis, Post-Translational Modifications, and Trafficking in Health and Disease.

Authors:  Trond Aasen; Scott Johnstone; Laia Vidal-Brime; K Sabrina Lynn; Michael Koval
Journal:  Int J Mol Sci       Date:  2018-04-26       Impact factor: 5.923

10.  AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy.

Authors:  Alexia Kagiava; Christos Karaiskos; Jan Richter; Christina Tryfonos; Matthew J Jennings; Amanda J Heslegrave; Irene Sargiannidou; Marina Stavrou; Henrik Zetterberg; Mary M Reilly; Christina Christodoulou; Rita Horvath; Kleopas A Kleopa
Journal:  Gene Ther       Date:  2021-03-10       Impact factor: 5.250

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.